Localised Prostate Cancer Treatment in Renal Transplant Patients: A Systematic Review

What is it about?

The systematic review aimed to assess treatment options for localized prostate cancer in renal transplant candidates and recipients. A total of 60 studies were identified, primarily retrospective non-randomized comparative or case series/reports of poor quality. Surgery and radiation therapy for localized prostate cancer in renal transplant patients appear equally efficacious. The mean age of patients was 61 years old, and the mean PSA level at diagnosis was 9.6 ng/mL. Given the limitations of this study, future research should concentrate on developing a multicentre RCT with long-term registry follow-up.

Featured Image

Why is it important?

This research is important because it systematically reviews and critically appraises all treatment options for localized prostate cancer in renal transplant candidates and recipients. It provides valuable insights into the risks and benefits of different treatment options and helps healthcare professionals make informed decisions about the best course of action for their patients. Key Takeaways: 1. The majority of studies included in the review were either retrospective non-randomized comparative or case series/reports of poor quality. 2. Surgery and radiation treatment for localized prostate cancer in renal transplant patients appear equally efficacious. 3. The cancer-specific survival results were similar between surgery and radiotherapy at 1 and 3 years. 4. The majority of patients had low-risk disease, with 78% undergoing surgery, 18% undergoing radiation therapy or brachytherapy, one patient undergoing focal therapy (HIFU), and 21 patients being placed on active surveillance. 5. All prostate cancer mortality cases were in high-risk prostate cancer (≥Gleason 8). 6. The quality of the included studies was generally low, and future research should concentrate on developing a multicentre RCT with long-term registry follow-up.